Log in

Relevant bibliographies by topics / Pathologic/drug therapy / Journal articles

To see the other types of publications on this topic, follow the link: Pathologic/drug therapy.

Journal articles on the topic 'Pathologic/drug therapy'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pathologic/drug therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

He, Yong-Gang, Zheng Wang, Jing Li, et al. "Pathologic complete response to conversion therapy in hepatocellular carcinoma using patient-derived organoids: A case report." World Journal of Gastrointestinal Oncology 16, no. 11 (2024): 4506–13. http://dx.doi.org/10.4251/wjgo.v16.i11.4506.

Full text

Abstract:

BACKGROUND For primary liver cancer, the key to conversion therapy depends on the effectiveness of drug treatment. Patient-derived tumor organoids have been demonstrated to improve the efficacy of conversion therapy by identifying individual-targeted effective drugs, but their clinical effects in liver cancer remain unknown. CASE SUMMARY We described a patient with hepatocellular carcinoma (HCC) who achieved pathologic complete response (pCR) to conversion therapy guided by the patient-derived organoid (PDO) drug sensitivity testing. Despite insufficiency of the remaining liver volume after he

APA, Harvard, Vancouver, ISO, and other styles

2

Arend, Lois J., and Tibor Nadasdy. "Emerging Therapy-Related Kidney Disease." Archives of Pathology & Laboratory Medicine 133, no. 2 (2009): 268–78. http://dx.doi.org/10.5858/133.2.268.

Full text

Abstract:

Abstract Context.—Many new therapies have emerged within the last 5 to 10 years to treat a variety of conditions. Several of these have direct or indirect renal toxicities that may go undiagnosed without careful attention of the pathologist to a patient's clinical history, particularly the addition of new medications or treatments. Objective.—To discuss patterns of renal injury resulting from medications or therapeutic regimens that have been introduced within the last 10 years. Recognition of these patterns may allow the pathologist to alert the attending clinician to a possible drug-induced

APA, Harvard, Vancouver, ISO, and other styles

3

Yong Lu, Da, Hong Ying Wu, and Ting Ren Lu. "HIV/AIDS treatment, therapeutic strategy break throughs." Hospice & Palliative Medicine International Journal 4, no. 2 (2020): 34–39. http://dx.doi.org/10.15406/hpmij.2020.04.00182.

Full text

Abstract:

HIV/AIDS is currently an incurable viral infectious disease characterized with life-long drug utility. To overcome this therapeutic setback, fatal pathological processes and different therapeutic mechanisms must be explored in broader-range and greater dimension. In this Article, the major types of global HIV/AIDS therapeutic strategies (pharmaceutical modification, herbal medicine, novel drug targets, drug combination modality, animal models, palliative medicine, immune-stimulate for HIV latency as well as HIV clearance by biological-based therapy) are especially highlighted. After novel path

APA, Harvard, Vancouver, ISO, and other styles

4

Hur, Junseok W. "Conservative treatment of senile spinal diseases: drug therapy and nerve block." Journal of the Korean Medical Association 64, no. 3 (2021): 185–90. http://dx.doi.org/10.5124/jkma.2021.64.3.185.

Full text

Abstract:

As we get closer to super-aged society, the prevalence of senile spinal diseases is constantly increasing and the burden on individuals and society grows high. Senile spinal disease is basically degenerative in nature. Pain and physical dysfunction occur due to various complex pathologic causes. For the diagnosis and treatment of such complex diseases, it is essential to understand common senile spinal diseases such as intervertebral disc herniation and spinal stenosis. Degenerative changes in intervertebral discs are caused by a combination of aging and excessive physical load, which results

APA, Harvard, Vancouver, ISO, and other styles

5

Ruff, Samantha M., and Timothy M. Pawlik. "A Review of Translational Research for Targeted Therapy for Metastatic Colorectal Cancer." Cancers 15, no. 5 (2023): 1395. http://dx.doi.org/10.3390/cancers15051395.

Full text

Abstract:

Colorectal cancer is the third most common cause of cancer-related death in the United States, with 20% of patients presenting with metastatic disease at the time of diagnosis. Metastatic colon cancer is often treated with a combination of surgery, systemic therapy (chemotherapy, biologic therapy, immunotherapy), and/or regional therapy (hepatic artery infusion pumps). Utilizing the molecular and pathologic features of the primary tumor to tailor treatment for patients may improve overall survival. Rather than a “one size fits all” approach, a more nuanced treatment plan guided by the unique f

APA, Harvard, Vancouver, ISO, and other styles

6

Sudo, Naohiro, and T. J. Yoo. "Effect of Anti-Inflammatory Drugs on Collagen-Induced Autoimmune Inner Ear Disease." Annals of Otology, Rhinology & Laryngology 97, no. 2 (1988): 153–58. http://dx.doi.org/10.1177/000348948809700212.

Full text

Abstract:

Animals that had collagen-induced autoimmune inner ear disease were treated with anti-inflammatory drugs: Solu-Medrol (steroid), sulindac (nonsteroid), or a combination of both. Temporal bones from drug-treated animals were examined for histopathologic and immunohistochemical changes, and sera were examined for levels of circulating antibody to type II collagen. Therapy was beneficial to the animals whether the drugs were administered alone or in combination; however, fewer lesions were observed in animals given either drug alone. Further, animals treated with steroid alone showed the least am

APA, Harvard, Vancouver, ISO, and other styles

7

Eristavi, S. Kh, R. V. Rozhivanov, E. R. Rozhivanova, E. N. Andreeva, G. A. Mel’nichenko, and N. G. Mokrysheva. "Gynecomastia: pathogenesis and approaches to treatment." Bulletin of Reproductive Health 4, no. 1 (2025): 32–38. https://doi.org/10.14341/brh12752.

Full text

Abstract:

Gynecomastia is a benign enlargement of the breast glands in men that can be physiologic, pathologic, or idiopathic. Physiologic gynecomastia can occur in children and during puberty. Pathologic gynecomastia is associated with various endocrine, genetic disorders, systemic diseases, paraneoplastic processes, or may be iatrogenic. Common causes of pathologic gynecomastia are hypogonadism, testicular or adrenal tumors producing estrogens, androgen excess syndromes with aromatization, androgen deficiencies, hepatopathy, and nephropathy. Most commonly, the underlying cause of gynecomastia is an im

APA, Harvard, Vancouver, ISO, and other styles

8

Liu, Kang, and Bolin Xie. "Today and Future of Age-Related Macular Degeneration." ISRN Ophthalmology 2012 (April 4, 2012): 1–9. http://dx.doi.org/10.5402/2012/480212.

Full text

Abstract:

Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 in developed countries. Understanding of the pathologic process, genetic mechanisms, and risk factors of this disease has the benefit of seeking newer and more effective treatment options. Current clinical therapy for AMD shows a dramatic change from a decade ago. Anti-VEGF drug therapy is regarded as the more effective treatment for neovascular AMD now, especially combining PDT therapy. In the future, the genetic and biochemical therapies may be the promising treatments for AMD. This paper will focus on

APA, Harvard, Vancouver, ISO, and other styles

9

Cagle, Philip T., and Lucian R. Chirieac. "Advances in Treatment of Lung Cancer With Targeted Therapy." Archives of Pathology & Laboratory Medicine 136, no. 5 (2012): 504–9. http://dx.doi.org/10.5858/arpa.2011-0618-ra.

Full text

Abstract:

Context.—Ongoing preclinical investigations and clinical trials involving new targeted therapies promise to improve survival for patients with lung cancer. Targeted therapeutic agents, based on genetic mutations and signaling pathways altered in lung cancer, have added significantly to our armamentarium for lung cancer treatment while minimizing drug toxicity. To date, 4 targeted therapies have been approved for treatment of lung cancer by the US Food and Drug Administration: gefitinib in 2002, erlotinib in 2003, bevacizumab in 2006, and crizotinib in 2011. Objective.—To review targeted therap

APA, Harvard, Vancouver, ISO, and other styles

10

Rastogi, Priya, Charles E. Geyer, Eleftherios P. Mamounas, and Angela DeMichele. "Drug Development: Neoadjuvant Opportunities in Breast Cancer." American Society of Clinical Oncology Educational Book, no. 33 (May 2013): 73–79. http://dx.doi.org/10.14694/edbook_am.2013.33.73.

Full text

Abstract:

Preoperative therapy allows for a higher rate of breast conserving surgery and has been shown equivalent to adjuvant therapy. Preoperative therapy provides an opportunity to obtain insights into breast cancer biology and to accelerate the evaluation of new therapies. Clinical trials have shown that women who achieve a pathologic complete response (pCR) have substantially improved outcomes compared with those who do not achieve a pCR. The U.S. Food and Drug Administration (FDA) meta-analysis demonstrated that the association of pCR and long-term outcomes is greater in women with aggressive brea

APA, Harvard, Vancouver, ISO, and other styles

11

Mamedli, Z. Z., A. V. Polynovskiy, D. V. Kuzmichev, S. I. Tkachev, and A. A. Aniskin. "Intensification of neoadjuvant therapy in patients with locally advanced rectal cancer." Pelvic Surgery and Oncology 11, no. 2 (2021): 19–28. http://dx.doi.org/10.17650/2686-9594-2021-11-2-19-28.

Full text

Abstract:

The aim of the study: to increase the frequency of achieving pathologic complete response and increase disease-free survival in the investigational group of patients with locally advanced rectal cancer T3(MRF+)–4N0–2M0 by developing a new strategy for neoadjuvant therapy.Materials and methods. In total, 414 patients were assigned to treatment. Control group I included 89 patients who underwent radiotherapy (RT) 52–56 Gy/26–28 fractions with concurrent capecitabine twice daily 5 days per week. Control group II included 160 patients who underwent RT 52–56 Gy/26–28 fractions with concurrent capec

APA, Harvard, Vancouver, ISO, and other styles

12

Lu, Charles, Roman Perez-Soler, Bilal Piperdi, et al. "Phase II Study of a Liposome-Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally and Pathologic Response Rates in Patients With Malignant Pleural Mesothelioma." Journal of Clinical Oncology 23, no. 15 (2005): 3495–501. http://dx.doi.org/10.1200/jco.2005.00.802.

Full text

Abstract:

Purpose To determine pathologic response rates to liposome-entrapped cis-bisneodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma. Patients and Methods Thirty-three patients with malignant pleural mesothelioma and free-flowing pleural effusions received intrapleural L-NDDP once every 3 weeks at a dose of 450 mg/m2. Thoracoscopic evaluation with pleural biopsies was performed before therapy and then after every two cycles. The primary end point was pathologic response as determined by thoracoscopic biopsy.

APA, Harvard, Vancouver, ISO, and other styles

13

Arai, Toshio, Kazutoyo Kogi, Yuki Honda, et al. "Lorazepam as a Cause of Drug-Induced Liver Injury." Case Reports in Gastroenterology 12, no. 2 (2018): 546–50. http://dx.doi.org/10.1159/000492209.

Full text

Abstract:

Lorazepam is a benzodiazepine derivative that is globally used for the therapy of anxiety and insomnia. A 51-year-old Japanese man with yellowish discoloration of the eyes and skin and pruritus was admitted due to liver dysfunction. He had taken lorazepam approximately 5 months prior to this admission. The clinical presentation and pathologic findings in the liver were consistent with drug-induced liver injury. After cessation of lorazepam, treatment with Stronger neo-minophagen C and ursodeoxycholic acid was started, and his liver injury resolved after 59 days. This case must serve as a warni

APA, Harvard, Vancouver, ISO, and other styles

14

Christoforidis, John B., Susie Chang, Angela Jiang, Jillian Wang, and Colleen M. Cebulla. "Intravitreal Devices for the Treatment of Vitreous Inflammation." Mediators of Inflammation 2012 (2012): 1–8. http://dx.doi.org/10.1155/2012/126463.

Full text

Abstract:

The eye is a well-suited organ for local delivery of therapeutics to treat vitreous inflammation as well as other pathologic conditions that induce visual loss. Several conditions are particularly challenging to treat and often require chronic courses of therapy. The use of implantable intravitreal devices for drug delivery is an emerging field in the treatment of vitreous inflammation as well as other ophthalmologic diseases. There are unique challenges in the design of these devices which include implants, polymers, and micro- and nanoparticles. This paper reviews current and investigational

APA, Harvard, Vancouver, ISO, and other styles

15

Tarhini, Ahmad A., Jennifer R. Eads, Kathleen N. Moore, et al. "Neoadjuvant immunotherapy of locoregionally advanced solid tumors." Journal for ImmunoTherapy of Cancer 10, no. 8 (2022): e005036. http://dx.doi.org/10.1136/jitc-2022-005036.

Full text

Abstract:

Definitive management of locoregionally advanced solid tumors presents a major challenge and often consists of a combination of surgical, radiotherapeutic and systemic therapy approaches. Upfront surgical treatment with or without adjuvant radiotherapy carries the risks of significant morbidities and potential complications that could be lasting. In addition, these patients continue to have a high risk of local or distant disease relapse despite the use of standard adjuvant therapy. Preoperative neoadjuvant systemic therapy has the potential to significantly improve clinical outcomes, particul

APA, Harvard, Vancouver, ISO, and other styles

16

Guancial, Elizabeth A., Deepak Kilari, Edward M. Messing, and Eric S. Kim. "Platinum concentration in bladder tissue treated with neoadjuvant chemotherapy and pathologic response." Journal of Clinical Oncology 33, no. 7_suppl (2015): 341. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.341.

Full text

Abstract:

341 Background: Platinum (Pt) resistance is a major limitation in the treatment of muscle-invasive bladder cancer (MIBC), for which Pt-based chemotherapy remains the standard of care. Reduced intratumoral drug accumulation is an important mechanism of platinum resistance. Our previous studies in lung cancer demonstrate significant correlation between tissue Pt concentration and tumor response to neoadjuvant chemotherapy (NAC). Tissue Pt concentration was measured in bladder specimens exposed to Pt-based NAC and correlated to pathologic response. Methods: A cohort of 19 clinically annotated, ar

APA, Harvard, Vancouver, ISO, and other styles

17

Naidoo, Jarushka, Xuan Wang, Kaitlin M. Woo, et al. "Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy." Journal of Clinical Oncology 35, no. 7 (2017): 709–17. http://dx.doi.org/10.1200/jco.2016.68.2005.

Full text

Abstract:

Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. Methods Patients who received anti–PD-1/PD-L1 monotherapy or in combination with anti–cytotoxic T-cell lymphocyte associated antigen-4 mAb were identified at two institutions (Memorial Sloan Kettering Cancer Center: advanced solid cancers, 2009 to 2014, and Melanoma Institute of Australia: melanomas only, 2013 to 2015). Pneumonitis was diagnosed by the treating inve

APA, Harvard, Vancouver, ISO, and other styles

18

Toto, Lisa, Luca Di Antonio, Olivia Costantino, and Rodolfo Mastropasqua. "Anti-VEGF Therapy in Myopic CNV." Current Drug Targets 22, no. 9 (2021): 1054–63. http://dx.doi.org/10.2174/1389450122999210128180725.

Full text

Abstract:

In this narrative-review, we report the most recent data from the literature of anti-vascular endothelial growth factor treatment for myopic choroidal neovascularization (mCNV). Myopic CNV is the most frequent sight-threatening complication of pathologic myopia. The natural course of mCNV can result in expanding macular atrophy and /or fibrosis, leading to irreversible visual loss after 5 years. Retinal multimodal imaging is mandatory for early diagnosis and monitoring of the disease during treatment. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is recommended as th

APA, Harvard, Vancouver, ISO, and other styles

19

Mizrak Kaya, Dilsa, Graciela M. Nogueras-Gonzalez, Prajnan Das, et al. "Efficacy of three-drug induction chemotherapy followed by preoperative chemoradiation in patients with localized gastric adenocarcinoma (GAC)." Journal of Clinical Oncology 37, no. 4_suppl (2019): 106. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.106.

Full text

Abstract:

106 Background: Preoperative induction chemotherapy followed by chemoradiation yields better R0 resection rates, pathologic complete response (pCR) rates and improved survival for localized GAC.Previous studies with two-drug induction chemotherapy showed 70-80% R0 resection rates and 20-30% pCR rates. We report the effect of three-drug induction chemotherapy on a large cohort of localized GAC patients. Methods: We identified 97 patients with localized GAC who received three-drug induction chemotherapy followed by preoperative chemoradiation therapy. We assessed various endpoints (overall survi

APA, Harvard, Vancouver, ISO, and other styles

20

Alrammahi, A., R. Almukhtar, and H. Qu. "Drug-induced thrombotic microangiopathy." American Journal of Clinical Pathology 160, Supplement_1 (2023): S51. http://dx.doi.org/10.1093/ajcp/aqad150.114.

Full text

Abstract:

Abstract Introduction/Objective Drug-induced thrombotic microangiopathy is observed in the patient on the new cancer therapy. It shares similar pathologic changes, as seen in conventional thrombotic microangiopathy, and is characterized by a pentad of hemolytic anemia, thrombocytopenia, renal dysfunction, fever, and neurological dysfunction. However, some patients may not have full scope of the pentad. Instead, only “diad” (hemolytic anemia and thrombopenia) exists, which could be mistakenly attributed to the drug side effect of bone marrow suppression. Methods/Case Report A 71-year-old white

APA, Harvard, Vancouver, ISO, and other styles

21

Poussel, Mathias, Karim Djaballah, Julien Laroppe, Béatrice Brembilla-Perrot, Pierre-Yves Marie, and Bruno Chenuel. "Left Ventricle Fibrosis Associated With Nonsustained Ventricular Tachycardia in an Elite Athlete: Is Exercise Responsible? A Case Report." Journal of Athletic Training 47, no. 2 (2012): 224–27. http://dx.doi.org/10.4085/1062-6050-47.2.224.

Full text

Abstract:

Objective: To emphasize the potentially harmful effects of high-intensity exercise on cardiac health and the fine line between physiologic and pathologic adaptation to chronic exercise in the elite athlete. This case also highlights the crucial need for regular evaluation of symptoms that suggest cardiac abnormality in athletes. Background: Sudden cardiac death (SCD) of young athletes is always a tragedy because they epitomize health. However, chronic, high-intensity exercise sometimes has harmful effects on cardiac health, and pathologic changes, such as myocardial fibrosis, have been observe

APA, Harvard, Vancouver, ISO, and other styles

22

Lauta, Vito Michele, Giuseppe Valerio, Anna Greco, and Marino Capece Minutolo. "Early-Onset Diagnosis of Lung Toxicity Caused by Cyclophosphamide, Melphalan and Procarbazine Therapy." Tumori Journal 73, no. 4 (1987): 351–58. http://dx.doi.org/10.1177/030089168707300406.

Full text

Abstract:

Lung function studis were performed in 33 patients with lymphomyeloproliferative diseases (25 cases of multiple myeloma and 8 cases of Hodgkin's disease) who received cyclophosphamide, procarbazine, and melphalan therapy. Lung function was investigated by spirometric tests, indicative tests of small airways disease, and diffusing capacity of the lung for carbon monoxide (DUCO). Indicative tests of small airways disease and other lung function tests such as forced expiratory volume in 1 second (FEY,), vital capacity (VC), total lung capacity (TLC) etc. were markedly improved in 18 patients (55%

APA, Harvard, Vancouver, ISO, and other styles

23

Jones, Robert Peter, Paul Sutton, Anahi Santoyo-Castelazo, et al. "Prediction of pathologic response of colorectal liver metastases (CRLM) to transcatheter hepatic therapy with irinotecan-eluting beads by hepatic activation of irinotecan." Journal of Clinical Oncology 31, no. 4_suppl (2013): 438. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.438.

Full text

Abstract:

438 Background: For patients with CRLM, good pathologic response to neoadjuvant chemotherapy is associated with improved overall survival. However, systemic therapy can increase postoperative morbidity and mortality. DEBIRI gives sustained delivery of drug directly to tumor, maximising response and reducing systemic exposure. Predictive markers of response would allow selection of patients most likely to benefit. This study assessed drug metabolism within normal hepatic parenchyma as a predictor of pathologic response of CRLM to DEBIRI. Methods: Patients with resectable CRLM received single ta

APA, Harvard, Vancouver, ISO, and other styles

24

Jeny, Florence, Hilario Nunes, and Dominique Valeyre. "Current Medical Therapy for Sarcoidosis." Seminars in Respiratory and Critical Care Medicine 38, no. 04 (2017): 523–31. http://dx.doi.org/10.1055/s-0037-1604032.

Full text

Abstract:

AbstractMost cases of sarcoidosis are mild and self-limited, with a spontaneous cure. However, in some patients, this disease may also be life-threatening, particularly when severe manifestations induce vital organ dysfunction. Sarcoidosis may also severely impair the quality of life through diverse, persistent disabling symptoms. To date, there is no curative treatment for sarcoidosis, but only anti-inflammatory drugs limiting the pathologic impact of sarcoidosis in reducing enhanced immunity reactions, granulomatous formation, and their consequences. Current anti-inflammatory treatments for

APA, Harvard, Vancouver, ISO, and other styles

25

Poushanchi, Behdod, Hiren Vallabh, and Justin Kupec. "Endoscopic and Pathologic Resolution of Chronic Nonsteroidal Anti-Inflammatory Drug-Induced Diaphragm-Like Colonic Strictures and Ulceration." Case Reports in Gastrointestinal Medicine 2018 (May 31, 2018): 1–3. http://dx.doi.org/10.1155/2018/7824081.

Full text

Abstract:

The chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) has steadily increased and, as a result, adverse effects have become more common. Isolated case reports have documented diaphragm-like colonic strictures and ulceration as the result of NSAID use. We report a unique case of this rare side effect with documented endoscopic and histologic healing of multiple proximal diaphragm-like colonic strictures and ulceration months after simple discontinuation of NSAID therapy.

APA, Harvard, Vancouver, ISO, and other styles

26

Boustros, Pamela, Lilia Maria Sanchez, Louis Gaboury, and Mona El Khoury. "Secretory Carcinoma of the Breast: Radiologic-Pathologic Correlation." Journal of Breast Imaging 6, no. 5 (2024): 520–28. http://dx.doi.org/10.1093/jbi/wbae041.

Full text

Abstract:

Abstract Secretory carcinoma is a rare, low-grade, special histological type of invasive breast carcinoma. Although it is the most common primary breast cancer in the pediatric population, most cases are diagnosed in adults, with a median age of 48 years (range 3 to 91 years). It most often presents as a painless and slowly growing palpable lump. Imaging findings are nonspecific. Secretory carcinomas have abundant periodic acid–Schiff positive intracytoplasmic and extracellular secretions on histopathology. Nearly all secretory carcinomas have mild to moderate nuclear pleomorphism with low mit

APA, Harvard, Vancouver, ISO, and other styles

27

Hillner, Bruce E., Jane C. Weeks, Christopher E. Desch, and Thomas J. Smith. "Pamidronate in Prevention of Bone Complications in Metastatic Breast Cancer: A Cost-Effectiveness Analysis." Journal of Clinical Oncology 18, no. 1 (2000): 72. http://dx.doi.org/10.1200/jco.2000.18.1.72.

Full text

Abstract:

PURPOSE: Pamidronate is effective in reducing bony complications in patients with metastatic breast cancer who have known osteolytic lesions. However, pamidronate does not increase survival and is associated with additional financial costs and inconvenience. We conducted a post-hoc evaluation of the cost-effectiveness of pamidronate using the results of two randomized trials that evaluated pamidronate 90 mg administered intravenously every month versus placebo. PATIENTS AND METHODS: The trials differed only in the initial systemic therapy administered (hormonal or chemotherapy). Total skeletal

APA, Harvard, Vancouver, ISO, and other styles

28

Ryabukhina, Yu E., O. L. Timofeeva, A. O. Akhov, et al. "The role of monoclonal antibodies in treatment of refractory multiple myeloma." MD-Onco 2, no. 1 (2022): 48–57. http://dx.doi.org/10.17650/2782-3202-2022-2-1-48-57.

Full text

Abstract:

Multiple myeloma (MM) is a B-cell malignant tumor; its morphological substrate – plasma cells – produces monoclonal immunoglobulin. Primarily, MM is diagnosed in elderly people and is characterized by a variety of clinical manifestations caused by plasma cells infiltration and organ damage. Despite successes in MM therapy, in the majority of cases recurrences of MM or refractory process are observed. In this case, the choice of antitumor drug is usually made depending on its tolerability, toxicity, and availability. Selection of correct treatment can be complicated by such frequent clinical ma

APA, Harvard, Vancouver, ISO, and other styles

29

Ankrah, Alfred O., Hans C. Klein, Lambert F. R. Span, et al. "The Role of PET in Monitoring Therapy in Fungal Infections." Current Pharmaceutical Design 24, no. 7 (2018): 795–805. http://dx.doi.org/10.2174/1381612824666171213101648.

Full text

Abstract:

Positron emission tomography (PET) is a powerful diagnostic nuclear medicine imaging technique. PET allows in vivo detection of a wide variety of physiologic and pathologic phenomena and it offers a noninvasive tool for the monitoring of therapy in various diseases. Invasive fungal infections (IFIs) are a global concern because of the increasing population of patients at risk of IFIs and the high morbidity and mortality. Therapy with antifungal agents is long-standing and expensive. The emerging resistant fungal strains make the management of IFIs challenging. There is an absolute need for a s

APA, Harvard, Vancouver, ISO, and other styles

30

Гутнова, Svetlana Gutnova, Тадтаева, and Diana Tadtaeva. "The study of systemic microcirculation and main clinical syndromes under the influence of combined and intravenous methods of laser therapy while chronic pancreatitis." Vladikavkaz Medico-Biological Bulletin 20, no. 29 (2014): 42–47. http://dx.doi.org/10.12737/11823.

Full text

Abstract:

The purpose of this study was to investigate the systemic microcirculation and main clinical syndromes under the influence of combined and intravenous methods of low-intensive laser therapy (LILT) in patients with chronic pancreatitis (ChP) in acute phase. 123 patients aged 36-77 years old were examined and divided into 2 groups: the experimental (78 patients) and the control group (45 patients). 30 men were in addition surveyed who composed the healthy group. The experimental group has had a complex drug and laser therapy of various therapeutic techniques: I subgroup – intravenous laser blood

APA, Harvard, Vancouver, ISO, and other styles

31

Booth, David C. "Combination Therapy in Pulmonary Arterial Hypertension: Gleaning a Practical Approach from the Randomized Trials." International Journal of Angiology 28, no. 02 (2019): 093–99. http://dx.doi.org/10.1055/s-0039-1691791.

Full text

Abstract:

AbstractIn the past decade, combination therapy in pulmonary arterial hypertension (PAH) has evolved from something PAH practitioners felt almost compelled to do, notwithstanding the absence of data, to a strategy proven by well-conducted randomized clinical trials. Whereas in the past, PAH treatment was limited to parenteral epoprostenol; today multiple drugs administrable either parenterally, inhaled, or orally have expanded the options for treating PAH patients. The SERIPHIN, AMBITION, and GRIPHON trials and emerging findings in FREEDOM-EV confirm the validity of a combined-therapy approach

APA, Harvard, Vancouver, ISO, and other styles

32

Pappo, Alberto S., and Uta Dirksen. "Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas." Journal of Clinical Oncology 36, no. 2 (2018): 168–79. http://dx.doi.org/10.1200/jco.2017.74.7402.

Full text

Abstract:

Several recent advances have been made in the diagnosis and therapy of malignant small round cell tumors that affect children, particularly in rhabdomyosarcoma, Ewing sarcoma, and other round cell sarcomas. These advances have provided new insights into the pathologic, histologic, and genomic characterization of specific tumor subtypes, which has led to the identification of novel therapeutic targets and improved stratification of risk. This has, in turn, led to improved efficacy in clinical trials of new drug combinations, thereby increasing the survival of patients with newly diagnosed and r

APA, Harvard, Vancouver, ISO, and other styles

33

Torelló, Jaime, José A. Durán, and María I. Serrano. "Diuretic Drug Utilization Study." Journal of Pharmacy Technology 12, no. 4 (1996): 169–76. http://dx.doi.org/10.1177/875512259601200412.

Full text

Abstract:

Objective: To evaluate the present use of diuretics in our institution, and determine the appropriateness of that use and the incidence of adverse reactions and interactions. Design: This retrospective study describes the indications for use of an identified drug or combination of drugs. By the time the data were collected, some patients had been discharged or had died. Setting: The study was carried out in a referral center, the University Hospital “Virgen Macarena,” Seville, Spain. Patients: All patients receiving diuretic therapy. Those undergoing hemodialysis or receiving home care were ex

APA, Harvard, Vancouver, ISO, and other styles

34

Szarfman, Ana, P. Murali Doraiswamy, Joseph M. Tonning, and Jonathan G. Levine. "Association Between Pathologic Gambling and Parkinsonian Therapy as Detected in the Food and Drug Administration Adverse Event Database." Archives of Neurology 63, no. 2 (2006): 299. http://dx.doi.org/10.1001/archneur.63.2.299-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Yee, Douglas, Rebecca Arielle Shatsky, Christina Yau, et al. "Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial." Journal of Clinical Oncology 40, no. 16_suppl (2022): 591. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.591.

Full text

Abstract:

591 Background: The I-SPY2 Trial evaluates multiple investigative agents in neoadjuvant breast cancer therapy with the primary endpoint of estimated pathologic complete response (pCR) rate. As a platform phase 2 trial it utilizes an adaptive design to compare new regimens with control chemotherapy (weekly paclitaxel followed by AC). Methods: Specific regimens are assigned based on clinically relevant signatures, including triple negative breast cancer (TNBC). Drug regimens graduate from the trial when the predicted pCR rate in any signature meets the pre-specified threshold of 85% probability

APA, Harvard, Vancouver, ISO, and other styles

36

Yee, Douglas, Rebecca Arielle Shatsky, Christina Yau, et al. "Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial." Journal of Clinical Oncology 40, no. 16_suppl (2022): 591. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.591.

Full text

Abstract:

591 Background: The I-SPY2 Trial evaluates multiple investigative agents in neoadjuvant breast cancer therapy with the primary endpoint of estimated pathologic complete response (pCR) rate. As a platform phase 2 trial it utilizes an adaptive design to compare new regimens with control chemotherapy (weekly paclitaxel followed by AC). Methods: Specific regimens are assigned based on clinically relevant signatures, including triple negative breast cancer (TNBC). Drug regimens graduate from the trial when the predicted pCR rate in any signature meets the pre-specified threshold of 85% probability

APA, Harvard, Vancouver, ISO, and other styles

37

Leite, Debora Inacio, Stefany de Castro Bazan Moura, Maria da Conceição Avelino Dias, et al. "A Review of the Development of Multitarget Molecules against HIV-TB Coinfection Pathogens." Molecules 28, no. 8 (2023): 3342. http://dx.doi.org/10.3390/molecules28083342.

Full text

Abstract:

The human immunodeficiency virus (HIV) produces the pathologic basis of acquired immunodeficiency syndrome (AIDS). An increase in the viral load in the body leads to a decline in the number of T lymphocytes, compromising the patient’s immune system. Some opportunistic diseases may result, such as tuberculosis (TB), which is the most common in seropositive patients. Long-term treatment is required for HIV-TB coinfection, and cocktails of drugs for both diseases are used concomitantly. The most challenging aspects of treatment are the occurrence of drug interactions, overlapping toxicity, no adh

APA, Harvard, Vancouver, ISO, and other styles

38

Xu, Xiuling, Katharina von Löhneysen, Katrin Soldau, Deborah Noack, Andrew Vu, and Jeffrey S. Friedman. "A novel approach for in vivo measurement of mouse red cell redox status." Blood 118, no. 13 (2011): 3694–97. http://dx.doi.org/10.1182/blood-2011-03-342113.

Full text

Abstract:

Abstract Maintenance of a reducing redox balance is a critical physiologic function of red cells (RBC) that can be perturbed in variety of RBC pathologies. Here we describe a new approach to evaluate in vivo RBC redox status using a redox sensitive GFP (roGFP2) sensor under control of a β-globin mini-promoter, directing expression specifically to erythroid cells. RoGFP2 expressing RBCs demonstrate ratiometric and reversible shifts in fluorescence on exposure to oxidants and reductants. We demonstrate that roGFP2 expressing RBC can be used to monitor thiol redox status during in vitro phenylhyd

APA, Harvard, Vancouver, ISO, and other styles

39

Cao, Yifeng, Chuyang Chen, Yi Tao, Weifeng Lin, and Ping Wang. "Immunotherapy for Triple-Negative Breast Cancer." Pharmaceutics 13, no. 12 (2021): 2003. http://dx.doi.org/10.3390/pharmaceutics13122003.

Full text

Abstract:

Triple-negative breast cancer (TNBC) is characterized by extensive tumor heterogeneity at both the pathologic and molecular levels, particularly accelerated aggressiveness, and terrible metastasis. It is responsible for the increased mortality of breast cancer patients. Due to the negative expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2, the progress of targeted therapy has been hindered. Higher immune response in TNBCs than for other breast cancer types makes immunotherapy suitable for TNBC therapy. At present, promising treatments in imm

APA, Harvard, Vancouver, ISO, and other styles

40

Aliev, K. A., V. V. Oleksenko, E. Yu Zyablitskaya, G. N. Telkieva, M. S. Kovalenko, and A. V. Kubyshkin. "Efficacy analysis of neoadjuvant chemotherapy regimens in patients with HER2/neunegative locally advanced breast cancer: A nonrandomized comparative study." Kuban Scientific Medical Bulletin 32, no. 2 (2025): 29–40. https://doi.org/10.25207/1608-6228-2025-32-2-29-40.

Full text

Abstract:

Background. In present times, no unified standard for selecting a neoadjuvant chemotherapy regimen for breast cancer exists. Although the efficacy of neoadjuvant chemotherapy has been confirmed by numerous clinical studies, tumor drug resistance develops in some cases, which reduces the expected effect of neoadjuvant chemotherapy. Currently, drug resistance to neoadjuvant chemotherapy is a major cause of treatment failure and one of the most challenging problems in the therapy of metastatic and locally advanced breast cancer. Objectives. To evaluate the efficacy of neoadjuvant chemotherapy in

APA, Harvard, Vancouver, ISO, and other styles

41

Georgijevic, Ana, and Zoran Tomic. "Photodynamic therapy of subfoveal choroidal neovascularization." Srpski arhiv za celokupno lekarstvo 135, no. 11-12 (2007): 629–34. http://dx.doi.org/10.2298/sarh0712629g.

Full text

Abstract:

Introduction Photodynamic therapy (PDT) is a method of treatment of choroidal neovascularization (CNV) with a diode laser used after intravenously administered verteporfin. Verteporfin is a light-activated drug initiating photochemical reactions in the target tissue. This leads to the selective occlusion of blood vessels in the CNV with no damage of photoreceptors, retinal pigment epithelium and retinal blood vessels. Objective To show the results of the treatment of predominantly classic subfoveal CNV with PDT with verteporfin used for the first time in our country. Method From 2003 to 2005,

APA, Harvard, Vancouver, ISO, and other styles

42

Chou, Chung-Tei. "How to Translate Basic Knowledge into Clinical Application of Biologic Therapy in Spondyloarthritis." Clinical and Developmental Immunology 2013 (2013): 1–6. http://dx.doi.org/10.1155/2013/369202.

Full text

Abstract:

Spondyloarthritis (SpA) is a family of many diseases, and these diseases share some clinical, genetic, and radiologic features. The disease process in the spine at the beginning is spinal inflammation, in which TNFαis the principal cytokine involved. Therefore, the dramatic clinical and pathologic response of anti-TNFαtherapy in SpA is based upon the presence of increased TNFαin synovial tissues and sacroiliac joints, which perpetuates chronic inflammation. The increased Toll-like receptors (TCR) 2 and 4 in the serum, peripheral blood mononuclear cells, or synovial tissues of ankylosing spondy

APA, Harvard, Vancouver, ISO, and other styles

43

Sharma, Priyanka, Roisin M. Connolly, Evanthia T. Roussos Torres, and Alastair Thompson. "Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer." American Society of Clinical Oncology Educational Book, no. 40 (May 2020): e1-e16. http://dx.doi.org/10.1200/edbk_281381.

Full text

Abstract:

Neoadjuvant systemic treatment of early-stage breast cancer has been used to improve resectability and reduce the extent of breast and axillary surgery. More recently, several other merits of neoadjuvant systemic treatment have emerged, including the ability to tailor clinically available adjuvant systemic therapy options based on pathologic response and to serve as a platform for early assessment of novel agents and response biomarkers and as an avenue for treatment optimization investigations (local and systemic therapy escalation and de-escalation trials guided by pathologic response). Atta

APA, Harvard, Vancouver, ISO, and other styles

44

Ortiz-Vitali, Jose L., and Radbod Darabi. "iPSCs as a Platform for Disease Modeling, Drug Screening, and Personalized Therapy in Muscular Dystrophies." Cells 8, no. 1 (2019): 20. http://dx.doi.org/10.3390/cells8010020.

Full text

Abstract:

Induced pluripotent stem cells (iPSCs) are the foundation of modern stem cell-based regenerative medicine, especially in the case of degenerative disorders, such as muscular dystrophies (MDs). Since their introduction in 2006, many studies have used iPSCs for disease modeling and identification of involved mechanisms, drug screening, as well as gene correction studies. In the case of muscular dystrophies, these studies commenced in 2008 and continue to address important issues, such as defining the main pathologic mechanisms in different types of MDs, drug screening to improve skeletal/cardiac

APA, Harvard, Vancouver, ISO, and other styles

45

Khavkin, A. I., A. Yu Trapeznikova, A. E. Razgonyaeva, V. V. Kholostova, and A. A. Kislenko. "Relationship of Crohn’s disease and acute pancreatitis in pediatric practice: literature review." Experimental and Clinical Gastroenterology, no. 6 (October 22, 2024): 188–93. http://dx.doi.org/10.31146/1682-8658-ecg-226-6-188-193.

Full text

Abstract:

Inflammatory bowel diseases (IBD) are a certain group of pathologic conditions of the gastrointestinal tract (GIT), including Crohn’s disease (CD) and ulcerative colitis (UC). In the modern world, vigilance for these diseases is growing, because their characteristic feature is the involvement of other organs in the pathological inflammatory process, as well as the development of local and systemic complications. As a rule, in children CCD occurs mainly at the age of 12-16 years. Recently, the attention of the medical world has been drawn to the issue of extraintestinal manifestations of CD. Pa

APA, Harvard, Vancouver, ISO, and other styles

46

Myhr, Gunnar. "Multimodal Cancer Treatment: Real Time Monitoring, Optimization, and Synergistic Effects." Technology in Cancer Research & Treatment 7, no. 5 (2008): 409–14. http://dx.doi.org/10.1177/153303460800700510.

Full text

Abstract:

The primary objective of this analysis is to provide the theoretical framework for a novel multimodal cancer treatment system emphasizing the use of ultrasound as a synergistic drug release mechanism, real time monitoring by MRI of hyperthermic, pO2, and ultrasound induced released effects. The aim is to provide a cure for the 20% of cancer victims who will die of complications from local solid tumors. Adjuvant therapy usually refers to surgery preceding or following chemotherapy and/or ionizing radiation treatment to decrease the risk of recurrence, but the absolute benefit for survival obtai

APA, Harvard, Vancouver, ISO, and other styles

47

Mao, Lili, Caili Li, Jie Dai, et al. "Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial." Journal of Clinical Oncology 43, no. 16_suppl (2025): 9512. https://doi.org/10.1200/jco.2025.43.16_suppl.9512.

Full text

Abstract:

9512 Background: The CAP 03 study demonstrated significant efficacy for camrelizumab combined with apatinib and temozolomide as first-line therapy for advanced acral melanoma (AM), achieving a 64.0% objective response rate and a median progression-free survival of 18.4 months. SWOG1801 and NADINA trials suggested that neoadjuvant therapy may provide greater benefits than adjuvant therapy in melanoma. CAP 03-NEO explores the efficacy and safety of this triple-drug regimen as neoadjuvant therapy in patients (pts) with resectable stage II/III AM. Methods: This two-stage clinical trial (ClinicalTr

APA, Harvard, Vancouver, ISO, and other styles

48

Dodd, M. Leann. "Association Between Pathologic Gambling and Parkinsonian Therapy as Detected in the Food and Drug Administration Adverse Event Database—Reply." Archives of Neurology 63, no. 2 (2006): 300. http://dx.doi.org/10.1001/archneur.63.2.300-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Rapoport, Bernardo L., Simon Nayler, Georgia S. Demetriou, Shun D. Moodley, and Carol A. Benn. "Triple Negative Breast Cancer Pathologic Diagnosis and Current Chemotherapy Treatment Options." Oncology & Hematology Review (US) 10, no. 01 (2014): 25. http://dx.doi.org/10.17925/ohr.2014.10.1.25.

Full text

Abstract:

Triple negative breast cancer (TNBC) comprises 12–20 % of all breast cancers and are a heterogeneous group of tumors, both clinically and pathologically. These cancers are characterized by the lack of expression of the hormone receptors estrogen receptor (ER) and progesterone receptor (PR), combined with the lack of either overexpression or amplification of the human epidermal growth factor receptor-2(HER2)gene. Conventional cytotoxic chemotherapy and DNA damaging agents continue to be the mainstay of treatment of this disease in the neoadjuvant, adjuvant, and metastatic setting. The lack of p

APA, Harvard, Vancouver, ISO, and other styles

50

Rapoport, Bernardo L., Simon Nayler, Georgia S. Demetriou, Shun D. Moodley, and Carol A. Benn. "Triple Negative Breast Cancer Pathologic Diagnosis and Current Chemotherapy Treatment Options." European Oncology & Haematology 10, no. 01 (2014): 35. http://dx.doi.org/10.17925/eoh.2014.10.1.35.

Full text

Abstract:

Triple negative breast cancer (TNBC) comprises 12–20 % of all breast cancers and are a heterogeneous group of tumours, both clinically and pathologically. These cancers are characterised by the lack of expression of the hormone receptors oestrogen receptor (OR) and progesterone receptor (PR), combined with the lack of either overexpression or amplification of the human epidermal growth factor receptor-2 (HER2) gene. Conventional cytotoxic chemotherapy and DNA damaging agents continue to be the mainstay of treatment of this disease in the neoadjuvant, adjuvant and metastatic setting. The lack o

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!